VHH Antibody Conjugates for Amyloid Beta Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and imaging amyloid β deposits in Alzheimer's disease and Down's syndrome, such as PET imaging and MRI, face challenges including radiation exposure, limited availability of radioactive compounds, low resolution, and inefficiency in crossing the blood-brain barrier, making them unsuitable for large-scale evaluation and routine diagnosis.
Innovation Solution
Development of VHH (variable domain of a camelid heavy-chain antibody) conjugates, specifically R3VQ and R3VE, which can cross the blood-brain barrier and are conjugated with MRI contrast agents like gadolinium, allowing for site-specific and non-site specific approaches to enhance imaging and therapeutic delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PET imaging and MRI are used to detect amyloid β deposits, then imaging capability is provided, but radiation exposure and limited availability of radioactive compounds occur
Solution Approach 1:
The patent uses VHH conjugates with MRI contrast agents instead of radioactive compounds. The VHH conjugates are non-radioactive, can be produced more easily, and do not require complex radioactive isotope production facilities, effectively replacing expensive and hazardous radioactive tracers with safer, more accessible alternatives.
Solution Approach 2:
The patent changes the detection parameter from radioactive signal detection (PET) to magnetic resonance signal detection (MRI). By conjugating VHH with MRI contrast agents like gadolinium, the detection mechanism shifts from measuring radioactive decay to measuring magnetic properties, eliminating radiation exposure while maintaining imaging capability.
2Reliability
If conventional antibodies are used for imaging, then antigen binding is achieved, but efficiency in crossing the blood-brain barrier is reduced
Solution Approach 1:
The patent segments the conventional antibody into its functional components and uses only the variable heavy-chain domain (VHH). This single-domain fragment retains antigen binding capability while reducing molecular size and complexity, enabling more efficient penetration through the blood-brain barrier compared to full-length antibodies.
Solution Approach 2:
The patent extracts the essential antigen-binding domain (VHH) from the complete antibody structure. By removing the constant regions and other non-essential portions, the VHH maintains its ability to recognize and bind amyloid β while achieving superior brain penetration due to its smaller size and optimized structure.
3Manufacturing precision
If site-specific conjugation methods are used, then manufacturing precision is improved, but process complexity increases
Solution Approach 1:
The patent introduces a cysteine residue as an intermediary at a specific position (position 229) of the VHH sequence. This engineered cysteine serves as a dedicated attachment point for maleimide-containing MRI contrast agents, enabling site-specific conjugation through thiol-maleimide chemistry while maintaining a relatively simple overall process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The VHH conjugates effectively recognize and image amyloid plaques in vivo, providing a safer and more efficient means for diagnosing and monitoring amyloid β deposits, while maintaining antigen binding properties and improving yield without side reactions.
Implementation Method 1
said cysteine residue C being linked by thio-addition to a substance of interest through a maleimido compound of formula (I) bearing said substance of interest
Implementation Method 2
The VHH conjugates effectively recognize and image amyloid plaques in vivo
Implementation Method 3
conjugated with MRI contrast agents like gadolinium, allowing for site-specific and non-site specific approaches to enhance imaging
Data Source
Figure 1
Figure 2A~2B
Figure 2C~2D
AI summary
The present invention relates to an oligopeptide and conjugates thereof. The present invention also relates to the use of these oligopeptide conjugates for treating or diagnosing disorders mediated by amyloid β deposits. Finally, the present invention also relates to a coupling method for obtaining oligopeptide coupled with a substance of interest (functional conjugates).